Driven by new insights into tumor biology and immune response, the therapeutic landscape for advanced renal cell carcinoma (RCC) continues to rapidly expand. As immunotherapy and VEGF-targeted combinations become central to RCC management, oncology teams must…
Neuroendocrine prostate cancer (NEPC) and other aggressive histologic variants of prostate cancer (PC) represent rare but clinically devastating disease phenotypes. These tumors progress rapidly and often evade detection through conventional measures such as PSA monitoring and…
Von Hippel-Lindau (VHL) disease is associated with a range of tumor types that require timely recognition and coordinated management. Accurate diagnosis depends on careful evaluation of clinical presentation, imaging findings, and genetic assessment, as these insights…
Von Hippel-Lindau (VHL) disease is a rare, heritable condition in which approximately 80% of affected individuals have an affected parent, underscoring the critical importance of early identification and surveillance. However, its rarity and variable presentation can…
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity…
Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of ongoing treatment continues to impact patient quality…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…
Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early…
Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…
The rapidly shifting therapeutic landscape for HER2-negative metastatic breast cancer (MBC) challenges clinicians to stay up-to-date on emerging clinical trial data, as well as recommendations on therapy selection and sequencing. Unfamiliarity with antibody-drug conjugate (ADC) treatment…